Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Shanghai Fosun Pharmaceutical Group CO Ltd (SFOSF)

Shanghai Fosun Pharmaceutical Group CO Ltd (SFOSF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 36.92
  • Price/Book 3.12
Trade SFOSF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5150 +1.12%
on 04/05/24
1.8975 -19.26%
on 03/15/24
-0.2980 (-16.28%)
since 03/08/24
3-Month
1.5150 +1.12%
on 04/05/24
2.1550 -28.91%
on 01/12/24
-0.6280 (-29.07%)
since 01/10/24
52-Week
1.5150 +1.12%
on 04/05/24
3.0275 -49.40%
on 04/13/23
-1.4330 (-48.33%)
since 04/10/23

Most Recent Stories

More News
Is Ardelyx is A Buy After Slip in Early 2022

Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them

ARDX : 6.39 (-1.84%)
CNCE : 8.37 (+0.12%)
KYKOF : 17.6300 (+4.76%)
SFOSF : 1.5320 (+1.12%)
KHTRF : 4.1900 (-2.33%)
ACIU : 2.38 (-1.65%)
BMEA : 10.98 (+1.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 1.5480
2nd Resistance Point 1.5400
1st Resistance Point 1.5360
Last Price 1.5320
1st Support Level 1.5240
2nd Support Level 1.5160
3rd Support Level 1.5120

See More

52-Week High 3.0275
Fibonacci 61.8% 2.4497
Fibonacci 50% 2.2713
Fibonacci 38.2% 2.0928
Last Price 1.5320
52-Week Low 1.5150

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar